Fredun Pharmaceuticals Ltd (FREDUN) Q1FY26 Concall Summary - Jun-2025 Qtr
Performance Overview
- Fredun Pharmaceuticals Ltd. reported strong Q1 FY26 results, driven by execution and a shift towards higher-margin verticals like pet healthcare.
- Revenue grew by 52% YoY, reaching INR 119.86 crore.
- Abytech, a specific product or segment, experienced 62% growth, reaching INR 16.99 crore, with margin expansion to 14.18%.
- Net profit increased by 64% to INR 6.77 crore.
- The company has a strong order book exceeding INR 200 crore.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.